2 results
Approved WMORecruiting
The main objectives Investigate a first signal of efficacy, safety and tolerability of BI 706321 in combination with ustekinumab treatment compared to placebo with ustekinumab treatment in patients with moderately to severely active CD at 12 weeks.…
Approved WMORecruiting
To assess the clinical impact of implementing a molecular urine test in the diagnostic workup of patients presenting with microscopic hematuria.